PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for the treatment of hepatitis C (HCV) will be made during the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) being held in Barcelona, Spain from April 11-15, 2007. The PSI-6130 studies were conducted through Pharmasset's HCV collaboration with Roche. Dr. Phillip Furman, Pharmasset's Vice President of Biological Sciences, will be presenting Pharmasset's posters beginning on Thursday, April 12, 2007 at 7:00pm (CEST). The complete abstracts can be viewed at http://www.easl.ch/liver-meeting.
Clevudine is Efficiently Phosphorylated to the Active Triphosphate form in Human Hepatocytes
C. Niu 1, E. Murakami 1, M.J. Otto 1, P.A. Furman 1 1 Pharmasset, Inc., Princeton, NJ, USA Study subject: initial half-life of the clevudine triphosphate.
Inhibition of HCV Replication by PSI-6130: Characterization of Activity in the HCV Replicon System
W.R. Jiang 1, S. Ali 1, S. Le Pogam 1, C. Daniel 1, S. Chiu 1, T. Kretz 1, I. Najera 1, P. Furman 2, N. Cammack 1, J. Symons 1
1 Roche Palo Alto LLC, Palo Alto, CA, USA; 2 Pharmasset Inc., Princeton, NJ, USA
Study subject: inhibition of HCV replication using combinations of PSI- 6130 with other HCV inhibitors.
Inhibition of HCV Replication by PSI-6130: Mechanism of Biochemical Activation and Inhibition
P.A. Furman 1, E. Murakami 1, H. Bao 1, J. Symons 2, M.J. Otto 1
1 Pharmasset, Inc., Princeton, NJ, USA; 2 Roche Palo Alto LLC, Palo Alto, CA, USA
Study subject: investigation of the enzymes involved in the